Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.

Lenders M, Neußer LP, Rudnicki M, Nordbeck P, Canaan-Kühl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand SM, Brand E.

J Am Soc Nephrol. 2018 Dec;29(12):2879-2889. doi: 10.1681/ASN.2018070740. Epub 2018 Nov 1.

PMID:
30385651
2.

Long-term Outcomes of Kidney Transplantation in Fabry Disease.

Ersözlü S, Desnick RJ, Huynh-Do U, Canaan-Kühl S, Barbey F, Genitsch V, Mueller TF, Cheetham M, Flammer AJ, Schaub S, Nowak A.

Transplantation. 2018 Nov;102(11):1924-1933. doi: 10.1097/TP.0000000000002252.

3.

Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.

Krämer J, Lenders M, Canaan-Kühl S, Nordbeck P, Üçeyler N, Blaschke D, Duning T, Reiermann S, Stypmann J, Brand SM, Gottschling T, Störk S, Wanner C, Sommer C, Brand E, Weidemann F.

Nephrol Dial Transplant. 2018 Aug 1;33(8):1362-1372. doi: 10.1093/ndt/gfx319.

PMID:
29186537
4.

Late-onset Bartter syndrome type II.

Gollasch B, Anistan YM, Canaan-Kühl S, Gollasch M.

Clin Kidney J. 2017 Oct;10(5):594-599. doi: 10.1093/ckj/sfx033. Epub 2017 May 8.

5.

Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.

Lenders M, Oder D, Nowak A, Canaan-Kühl S, Arash-Kaps L, Drechsler C, Schmitz B, Nordbeck P, Hennermann JB, Kampmann C, Reuter S, Brand SM, Wanner C, Brand E.

J Intern Med. 2017 Sep;282(3):241-253. doi: 10.1111/joim.12647. Epub 2017 Jul 26.

6.

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.

Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E.

Orphanet J Rare Dis. 2016 Jun 29;11(1):88. doi: 10.1186/s13023-016-0473-4.

7.

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.

Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E.

Orphanet J Rare Dis. 2016 May 4;11(1):54. doi: 10.1186/s13023-016-0441-z.

8.

Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.

Lenders M, Canaan-Kühl S, Krämer J, Duning T, Reiermann S, Sommer C, Stypmann J, Blaschke D, Üçeyler N, Hense HW, Brand SM, Wanner C, Weidemann F, Brand E.

J Am Soc Nephrol. 2016 Mar;27(3):952-62. doi: 10.1681/ASN.2015030337. Epub 2015 Jul 16.

9.

Endomyocardial biopsy in Anderson-Fabry disease: The key in uncertain cases.

Tschöpe C, Dominguez F, Canaan-Kühl S, Blaschke D, Kühl U, Pieske B, Haverkamp W.

Int J Cardiol. 2015;190:284-6. doi: 10.1016/j.ijcard.2015.04.130. Epub 2015 Apr 17. No abstract available.

PMID:
25932808
10.

Structural and functional cardiac analyses using modern and sensitive myocardial techniques in adult Pompe disease.

Morris DA, Blaschke D, Krebs A, Canaan-Kühl S, Plöckinger U, Knobloch G, Walter TC, Kühnle Y, Boldt LH, Kraigher-Krainer E, Pieske B, Haverkamp W.

Int J Cardiovasc Imaging. 2015 Jun;31(5):947-56. doi: 10.1007/s10554-015-0629-7. Epub 2015 Mar 6.

PMID:
25744427
11.

Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status.

Morris DA, Blaschke D, Canaan-Kühl S, Krebs A, Knobloch G, Walter TC, Haverkamp W.

Int J Cardiovasc Imaging. 2015 Feb;31(2):301-13. doi: 10.1007/s10554-014-0551-4. Epub 2014 Oct 15.

PMID:
25315709
12.

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E.

J Am Soc Nephrol. 2014 Apr;25(4):837-49. doi: 10.1681/ASN.2013060585. Epub 2014 Feb 20.

13.

[Pain therapy for Fabry's disease].

Sommer C, Uçeyler N, Duning T, Arning K, Baron R, Brand E, Canaan-Kühl S, Hilz M, Naleschinski D, Wanner C, Weidemann F.

Internist (Berl). 2013 Jan;54(1):121-2, 124-30. doi: 10.1007/s00108-012-3204-5. Review. German.

PMID:
23250563
14.

Detection and characterization of antibodies against recombinant human erythropoietin by RIPA, ELISA and neutralization assay in patients with renal anemia.

Gross J, Moller R, Bischoff S, Canaan-Kühl S, Fromme M, Henke W.

J Immunol Methods. 2008 Jul 31;336(2):152-8. doi: 10.1016/j.jim.2008.04.009. Epub 2008 May 5.

PMID:
18501920
15.

"Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis.

Kallinich T, Haffner D, Rudolph B, Schindler R, Canaan-Kühl S, Keitzer R, Burmester GR, Roesen-Wolff A, Roesler J.

Ann Rheum Dis. 2006 Jul;65(7):958-60. Epub 2005 Nov 24.

16.

C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo.

Canaan-Kühl S, Ostendorf T, Zander K, Koch KM, Floege J.

Kidney Int. 1998 May;53(5):1143-51.

17.

Endogenous ANP in postischemic acute renal allograft failure.

Vinot O, Bialek J, Canaan-Kühl S, Scandling JD Jr, Dafoe D, Alfrey E, Myers BD.

Am J Physiol. 1995 Jul;269(1 Pt 2):F125-33.

PMID:
7631826
18.

Relationships among protein and albumin concentrations and oncotic pressure in nephrotic plasma.

Canaan-Kühl S, Venkatraman ES, Ernst SI, Olshen RA, Myers BD.

Am J Physiol. 1993 Jun;264(6 Pt 2):F1052-9.

PMID:
8322891
19.

The natriuretic peptides and their receptors.

Jamison RL, Canaan-Kühl S, Pratt R.

Am J Kidney Dis. 1992 Nov;20(5):519-30. Review.

PMID:
1442767
20.

Regulation of platelet clearance receptors for atrial natriuretic peptide in diabetic nephropathy.

Canaan-Kuhl S, Parra-Roide L, Bialek JW, Jamison RL, Myers BD.

J Am Soc Nephrol. 1992 Aug;3(2):236-43.

21.

Identification of "B" receptor for natriuretic peptide in human kidney.

Canaan-Kühl S, Jamison RL, Myers BD, Pratt RE.

Endocrinology. 1992 Jan;130(1):550-2. Erratum in: Endocrinology 1992 Apr;130(4):2283.

PMID:
1309350

Supplemental Content

Loading ...
Support Center